Free Trial

Zevra Therapeutics Q4 2023 Earnings Report

Zevra Therapeutics logo
$7.43 -0.23 (-3.00%)
As of 04/3/2025 04:00 PM Eastern

Zevra Therapeutics EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.20
Beat/Miss
Missed by -$0.20
One Year Ago EPS
N/A

Zevra Therapeutics Revenue Results

Actual Revenue
$13.22 million
Expected Revenue
$13.35 million
Beat/Miss
Missed by -$130.00 thousand
YoY Revenue Growth
N/A

Zevra Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Zevra Therapeutics Earnings Headlines

Zevra Therapeutics: Mixed Feelings On Miplyffa Approval
Zevra Therapeutics Files Preliminary Proxy
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Zevra Therapeutics management to meet with Cantor Fitzgerald
See More Zevra Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zevra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zevra Therapeutics and other key companies, straight to your email.

About Zevra Therapeutics

Zevra Therapeutics (NASDAQ:ZVRA) discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

View Zevra Therapeutics Profile

More Earnings Resources from MarketBeat